DK0643726T3 - Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei - Google Patents

Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei

Info

Publication number: DK0643726T3
Authority: DK; Denmark
Prior art keywords: human; protein; pct; compositions; cell response
Prior art date: 1992-05-26

Application number

DK93913627T

Other languages

English (en)

Inventor

Cornelis Joseph Maria Melief

Wybe Martin Kast

Original Assignee

Seed Capital Investments

Univ Leiden

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-26

Filing date

1993-05-18

Publication date

2000-03-20

1993-05-18 Application filed by Seed Capital Investments, Univ Leiden filed Critical Seed Capital Investments

2000-03-20 Application granted granted Critical

2000-03-20 Publication of DK0643726T3 publication Critical patent/DK0643726T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

DK93913627T 1992-05-26 1993-05-18 Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei DK0643726T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP92201510		1992-05-26
PCT/NL1993/000102 WO1993024525A1 (en)	1992-05-26	1993-05-18	PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES

Publications (1)

Publication Number	Publication Date
DK0643726T3 true DK0643726T3 (da)	2000-03-20

Family

ID=8210629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93913627T DK0643726T3 (da)	1992-05-26	1993-05-18	Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei

Country Status (11)

Country	Link
US (1)	US5679641A (da)
EP (1)	EP0643726B1 (da)
JP (2)	JPH08501280A (da)
AT (1)	ATE183514T1 (da)
AU (1)	AU681853B2 (da)
CA (1)	CA2136624A1 (da)
DE (1)	DE69326064T2 (da)
DK (1)	DK0643726T3 (da)
ES (1)	ES2139012T3 (da)
GR (1)	GR3031919T3 (da)
WO (1)	WO1993024525A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994002167A1 (en) *	1992-07-22	1994-02-03	The Trustees Of Princeton University	p53 VACCINE
FR2698367B1 (fr) *	1992-11-02	1995-02-17	Eurobio Lab	Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
CN1118572A (zh) *	1993-03-05	1996-03-13	萨依特尔有限公司	Hla-a2.1组合肽及其用途
WO1995004817A1 (en) *	1993-08-06	1995-02-16	Cytel Corporation	Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
FR2722207B1 (fr) *	1994-07-07	1996-09-27	Inst Nat Sante Rech Med	Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules
EP0793501A4 (en) *	1994-12-14	2000-05-03	Scripps Research Inst	IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
US5925799A (en) *	1996-03-12	1999-07-20	Abb Lummus Global Inc.	Catalytic distillation and hydrogenation of heavy unsaturates in an olefins plant
NZ331688A (en) *	1996-03-28	2000-02-28	Univ Johns Hopkins	Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en)	1996-03-28	2002-10-01	The Johns Hopkins University	Molecular complexes which modify immune responses
US6218363B1 (en) *	1996-08-28	2001-04-17	Thomas Jefferson University	MHC peptides and methods of use
SE9604581D0 (sv) *	1996-12-12	1996-12-12	Karolinska Innovations Ab	An agent against cancer and virus infections
US6268411B1 (en)	1997-09-11	2001-07-31	The Johns Hopkins University	Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
CA2321026A1 (en) *	1998-03-09	1999-09-16	Zealand Pharmaceuticals A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801695D0 (sv) *	1998-05-14	1998-05-14	Karolinska Innovations Ab	Inhibition of p53 function by a p53-derived peptide
ATE429247T1 (de) *	1998-06-17	2009-05-15	Idm Pharma Inc	Hla-bindende peptide und ihre verwendungen
AU3755800A (en) *	1999-03-15	2000-10-04	Introgen Therapeutics, Inc.	Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
TW410377B (en) *	1999-06-17	2000-11-01	Taiwan Semiconductor Mfg	Method of planarization and the apparatus of the same
DE60030450T2 (de) *	1999-09-08	2007-08-30	Transgene S.A.	Von MUC-1 abgeleitete Peptide
FR2794368A1 (fr) *	1999-10-07	2000-12-08	Biovector Therapeutics	Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
WO2001041788A1 (en) *	1999-12-10	2001-06-14	Epimmune, Inc.	INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
AU2001275246B2 (en) *	2000-06-05	2006-06-29	Altor Bioscience Corporation	T cell receptor fusions and conjugates and methods of use thereof
DE10109855A1 (de) *	2001-03-01	2002-09-12	Stanislawski Thomas	Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
CA2487779C (en) *	2001-06-05	2012-10-02	Altor Bioscience Corporation	P53 binding t cell receptor molecules and uses thereof
WO2003006043A1 (en)	2001-07-10	2003-01-23	Massachusetts Institute Of Technology	Surfactant peptide nanostructures, and uses thereof
JP5068931B2 (ja) *	2002-07-12	2012-11-07	ザジョンズホプキンスユニバーシティー	独自のクローン形質のリンパ球受容体に結合する試薬および方法
EP1888105A2 (en) *	2005-05-12	2008-02-20	Introgen Therapeutics, Inc.	P53 vaccines for the treatment of cancers
AU2006289683A1 (en) *	2005-09-07	2007-03-15	Receptor Logic, Ltd.	Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2008021160A2 (en) *	2006-08-17	2008-02-21	Trustees Of Boston University	Regulation of litaf modulated cytokine production by a novel p53 short peptide
PL2118123T3 (pl)	2007-01-31	2016-06-30	Dana Farber Cancer Inst Inc	Stabilizowane peptydy p53 i ich zastosowania
KR101525754B1 (ko)	2007-03-28	2015-06-09	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	스티칭된 폴리펩티드
CA2807685C (en)	2010-08-13	2020-10-06	Aileron Therapeutics, Inc.	P53 derived peptidomimetic macrocycle
TW201806968A (zh)	2011-10-18	2018-03-01	艾利倫治療公司	擬肽巨環化合物
CA2864120A1 (en)	2012-02-15	2013-08-22	Aileron Therapeutics, Inc.	Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112014020103A2 (pt)	2012-02-15	2018-10-09	Aileron Therapeutics, Inc.	macrociclos peptidomiméticos
KR20150082307A (ko)	2012-11-01	2015-07-15	에일러론 테라퓨틱스 인코포레이티드	이치환 아미노산 및 이의 제조 및 사용 방법
SG10201902598VA (en)	2014-09-24	2019-04-29	Aileron Therapeutics Inc	Peptidomimetic macrocycles and formulations thereof
MX2017003797A (es)	2014-09-24	2017-06-15	Aileron Therapeutics Inc	Macrociclos peptidomimeticos y usos de los mismos.
US10253067B2 (en)	2015-03-20	2019-04-09	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
CN108368161A (zh)	2015-09-10	2018-08-03	艾瑞朗医疗公司	作为mcl-1调节剂的拟肽大环化合物
CA3080274A1 (en) *	2017-09-29	2019-04-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
WO2020023502A1 (en)	2018-07-23	2020-01-30	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
US12453774B2 (en)	2019-11-07	2025-10-28	Genoimmune Therapeutics Co., Ltd.	Tumor immunotherapy polypeptide and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO312681B1 (no) *	1990-08-24	2002-06-17	Univ California	Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet

1993
- 1993-05-18 WO PCT/NL1993/000102 patent/WO1993024525A1/en not_active Ceased
- 1993-05-18 DE DE69326064T patent/DE69326064T2/de not_active Expired - Fee Related
- 1993-05-18 AT AT93913627T patent/ATE183514T1/de not_active IP Right Cessation
- 1993-05-18 JP JP6500408A patent/JPH08501280A/ja active Pending
- 1993-05-18 US US08/338,634 patent/US5679641A/en not_active Expired - Fee Related
- 1993-05-18 DK DK93913627T patent/DK0643726T3/da active
- 1993-05-18 AU AU43591/93A patent/AU681853B2/en not_active Ceased
- 1993-05-18 ES ES93913627T patent/ES2139012T3/es not_active Expired - Lifetime
- 1993-05-18 CA CA002136624A patent/CA2136624A1/en not_active Abandoned
- 1993-05-18 EP EP93913627A patent/EP0643726B1/en not_active Expired - Lifetime
1999
- 1999-11-19 GR GR990403009T patent/GR3031919T3/el unknown
2003
- 2003-07-09 JP JP2003194583A patent/JP2004123708A/ja active Pending

Also Published As

Publication number	Publication date
EP0643726A1 (en)	1995-03-22
JPH08501280A (ja)	1996-02-13
EP0643726B1 (en)	1999-08-18
WO1993024525A1 (en)	1993-12-09
ATE183514T1 (de)	1999-09-15
CA2136624A1 (en)	1993-12-09
AU4359193A (en)	1993-12-30
DE69326064D1 (de)	1999-09-23
DE69326064T2 (de)	2000-05-25
AU681853B2 (en)	1997-09-11
GR3031919T3 (en)	2000-03-31
ES2139012T3 (es)	2000-02-01
JP2004123708A (ja)	2004-04-22
US5679641A (en)	1997-10-21

Publication	Publication Date	Title
DK0643726T3 (da)	2000-03-20	Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
ATE415173T1 (de)	2008-12-15	Pan dr-bindeproteinen zur erhöhung der immunantwort
IL105554A0 (en)	1993-08-18	Peptides of human papilloma virus for use in human t cell response inducing compositions
TR199802423T2 (xx)	1999-02-22	Konsantre antikor terkibi.
DE69726426D1 (de)	2004-01-08	Unterdrückung von immunantwort durch hemmung von cathepsin s
DK0479948T3 (da)	1999-05-25	Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
DE69931482D1 (de)	2006-06-29	Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DK0633763T3 (da)	1997-12-29	Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
NO952385D0 (no)	1995-06-16	Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen
DK1021534T3 (da)	2010-02-01	Hepatitis C-receptorprotein CD81
NO963487L (no)	1996-08-28	Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
DE59508137D1 (de)	2000-05-11	Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
FR2724320B1 (fr)	1996-12-20	Nouvel implant pour le traitement des maladies acquises
PT723552E (pt)	2003-02-28	Oligopeptidos derivados de fragmentos de proteina reactiva c
TR199902866T2 (xx)	2000-02-21	Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
TR199700842T1 (xx)	1998-01-21	�nsan DNase I Varyantlar�.
DK1039931T3 (da)	2005-08-08	Multivalente rekombinante antistoffer til at behandle HRV infektioner
AU1318797A (en)	1997-08-20	Peptides and uses thereof for therapy of celiac diseases
TR199802387T2 (xx)	1999-03-22	Do�um kontrol� i�in kullan�lan Zona Pellucida proteinleri.
ATE230027T1 (de)	2003-01-15	Menschliche dnase i varianten
NZ511034A (en)	2004-03-26	Methods of downmodulating the immune response to therapeutic proteins
DK0938555T3 (da)	2005-05-23	Konstruktioner og komplekser af cyclin E
DK0999849T3 (da)	2003-01-06	Anvendelse af LBP til sepsisbehandling
UA9703A (uk)	1996-09-30	Антипротеіназний засіб
BRPI0216042B8 (pt)	2021-05-25	polipeptídeo capaz de se ligar a ang-2, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso dos referidos polipeptídeos.